The remaining undisclosed project wins are confidential licensing arrangements with large pharmaceutical companies, where Oxford Genetics is providing its proprietary cell lines and viral vectors for the discovery and development of viral therapies. Oxford Instruments will begin scaling up its gene therapy manufacturing services after being awarded six licencing deals for the technologies . The deals include a licence from Aldevron to bring Oxford 's Lentiviral Plasmids therapy to market and a collaborative project with Sphere ##s to develop automated microfluidic systems for gene therapy in mammalian cells . The remaining agreements are confidential deals negotiated with large pharmaceutical firms .
Oxford Instruments will begin scaling up its gene therapy manufacturing services after being awarded six licencing deals for the technologies . The deals include a licence from Aldevron to bring Oxford 's Lentiviral Plasmids therapy to market and a collaborative project with Sphere ##s to develop automated microfluidic systems for gene therapy in mammalian cells . The remaining agreements are confidential deals negotiated with large pharmaceutical firms .